Jim Kramer here to share with you a sample of my take on the market from today's CNBC Investing Club warning meeting.

Let's talk a little because I think the good results are being overshadowed by announcements by CVS.

So it was a top and bottom line beat. You did have a revenue beat for the GLP1 franchise, both Zepound and Manjaro.

Slightly beat expectations. It wasn't a big beat, but one percent. But they did have a miss,

you know, in the last couple quarters, so this was positive to see.

Call just started at 10, so not on it, but the news that's really impacting the stock is CVS

today, formed a partnership with Nova Nordus. Starting July 1st, CVS CARAMARC will prioritize

Wagovi on its list of covered drugs, making it the preferred GLP1 for obesity. Some concern

that this will slow script momentum for Eli Lilly's products. It also could impact pricing too, right? So again,

I'm sure it's being addressed on the call that's happening right now. But the big reason why Lilly

had the spike from the low 700s just the other week was good data on their pill, the obesity

pill, or for Glypropro. Which is not going away. It's just getting closer and closer. Sure. And it gives you Wagovi-like efficacy with solid tolerability, good safety profile. It's once daily versus once weekly injection. People are going to prefer to take the pill. It's just an easier to use. And by the way, it doesn't have been

kept cold. So it's ideal to ship to China and India, where there are 200 million people, Dave Ricketts, that are going to need it. So storage-wise, there's also benefits as well, really important. Let's just talk trading for a second. Okay, so you're holding it because you thought it was going to be a blog quarter or you didn't expect the CBS. Now, you're dumping it.

Now, when do you get back in if you're one of those people? Do you get back in betting that the pill comes out? They have positive data. There's be something good for the FDA. You don't know when to get back in. So the answer is don't leave. Yeah, and that pill, Rick thinks it could be approved as soon as early next year. They've pre-built inventory for it.

So the launch, they are ready.

No supply shortage, just like what they've been things that could be approved as soon as early next year. They've pre-built inventory for it.

So the launch, they are ready.

No supply shortage.

Just like what the drugs have been facing for quite some time,

although not in shortage anymore.

Join the CBC Investing Club with Jim Kramer to catch my member exclusive morning minis every day at 1020 a.m.

Visit cnbc.com slash morning take to become a member today.

...